Core Viewpoint - The company announced that its wholly-owned subsidiary, Sirnaomics, Inc., has completed the Phase I trial of the investigational drug STP707 and has formally submitted the clinical study report to the FDA [1] Group 1: Clinical Trial Details - The study included adults with advanced, metastatic, or unresectable solid tumors that have spread or cannot be surgically removed, and whose cancer has stopped responding to standard treatments [1] - STP707 demonstrated clear clinical activity in these patients, with some achieving disease stabilization, and it delayed disease progression in a population with limited treatment options and prior multiple lines of therapy [1] - Patients received different doses of STP707 via intravenous administration, and the early-stage conclusion indicates that STP707 can be administered at multiple doses with mostly manageable side effects [1] Group 2: Future Development Plans - The completion of the Phase I trial and submission of the clinical study report is considered a key milestone for STP707 [1] - Following the submission of the clinical study report, Sirnaomics, Inc. is preparing to initiate discussions with the FDA to determine the Phase II development strategy [1]
圣诺医药-B完成试验药物STP707的I期试验并已向FDA正式提交临床研究报告